Navigation Links
Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
Date:1/10/2008

INCHEON, South Korea, Jan. 10 /PRNewswire/ -- Celltrion, Inc., a Korean biopharmaceutical company whose core business is currently contract manufacturing, and CSL Limited, Australia's leading biopharmaceutical company, announced today the signing of an agreement for the development and supply of CSL 360, an experimental monoclonal antibody therapy for the treatment of acute myeloid leukemia (AML). Phase I clinical trials for CSL 360 are currently being conducted by CSL in Australia.

As part of the collaboration, Celltrion will provide process development expertise and supply clinical and commercial material to support the clinical development program for CSL 360 and commercialization of the product, with the potential for a longer term strategic manufacturing relationship between the companies in the future.

"Celltrion and its employees are completely committed to world-class quality in biopharmaceutical manufacturing, to assisting CSL in achieving the successful completion of clinical trials, and to providing manufacturing support for CSL's product commercialization," said Jung-Jin Seo, Celltrion's Chairman and Chief Executive Officer.

"Superior quality biopharmaceutical manufacturing facilities of this type are a scarce commodity in this region and we are delighted to have signed this collaboration to provide CSL with the opportunity to facilitate the clinical development of CSL 360 and potentially other exciting future recombinant protein opportunities," said Dr. Brian McNamee, CSL's Chief Executive Officer.

About Celltrion

Celltrion, established in 2002, is a contract manufacturing organization with a headquarters in Incheon, South Korea. Celltrion, an emerging leader in the biopharmaceutical industry, is dedicated to providing high quality services to accelerate product development, while offering scalable manufacturing capabilities for our clients and business partners. Celltrion is also investing in research and development of its own products, as well as licensing from biopharmaceutical research companies throughout the world, in order to develop into a fully integrated biotechnology company. For more information, please visit Celltrion's website at http://www.celltrion.com.

About CSL Limited

Headquartered in Melbourne, Australia, CSL Limited (ASX: CSL) is a global, specialty biopharmaceutical company that develops, manufactures and markets protein-based medicines to treat and prevent serious human medical conditions. The CSL Group has a combined heritage of outstanding contributions to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. Our strong commitment to funding research and development of protein based biological medicines for unmet medical needs underpins our continuing growth.

The CSL Group includes CSL Bioplasma, CSL Biotherapies and CSL Behring incorporating ZLB Plasma. With major facilities in Australia, Germany, Switzerland and the U.S., CSL has over 8,600 employees operating in 27 countries.

For additional information, please contact:

Seung-Suh Hong, Ph.D.

Senior Vice President - Business Development

Celltrion, Inc. (U.S.A.)

Email: seungsuh.hong@celltrion.com

Tel: + 1 650 766 2307


'/>"/>
SOURCE Celltrion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... to their offering. ... The global fluoropolymer market in the healthcare industry to grow ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:1/17/2017)... , Jan. 17, 2017 Following an ... today praised the Food and Drug Administration,s (FDA,s) ... Human Drug Products by Pharmacies and Outsourcing Facilities." ... proposed limitation on pre-packaging -- which would have ... costs to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... ReportsnReports.com adds "Anaphylaxis - Pipeline Review, H2 2016" ... Anaphylaxis,s therapeutic pipeline with comprehensive information on the therapeutic development ... assessment by drug target, mechanism of action (MoA), route of ... featured news and press releases. ... Complete report on H2 2016 pipeline ...
Breaking Medicine Technology:
(Date:1/17/2017)... York (PRWEB) , ... January 17, 2017 , ... ... – SightMD – will lecture to primary eye care practitioners on the latest ... at the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... financial planning assistance to families and business professionals throughout central Colorado, is joining ... homeless families. , The Aurora Warms The Night organization is committed to breaking ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... and breast cancer survivor Sandra Lee as keynote speaker for the 34th Annual ... Florida. , In making the announcement, PER® president, Phil Talamo, said, “We are ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a ... announced a new agreement as part of a long-term extension of their media partnership. ... the airing of some of the sport’s premier events exclusively on FloWrestling.com as well ...
(Date:1/16/2017)... ... ... California Southern University has named Dr. Steven Beazley University President. ... a core faculty member, teaching master’s and doctoral courses in the university’s School of ... where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also has ...
Breaking Medicine News(10 mins):